Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Oncology|September 10, 2025
A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOXRafael Álvarez-Gallego, Teresa Macarulla, Berta Laquente, et al.
International Journal of Colorectal Disease|December 5, 2023
Light and shadow of watch-and-wait strategy in rectal cancer: oncological result, clinical outcomes, and cost-effectiveness analysisValentina Ferri, Emilio Vicente, Yolanda Quijano, et al.
Cancer Medicine|August 21, 2018
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancerDavid Fogelman, Antonio Cubillo, Pilar García-Alfonso, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2018
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorinRichard A Hubner, Antonio Cubillo, Jean-Frédéric Blanc, et al.
American Journal of Clinical Oncology|July 6, 2018
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal CancerAntonio Cubillo, Rafael Álvarez-Gallego, Manuel Muñoz, et al.
Oncotarget|November 17, 2016
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximabRodrigo A Toledo, Antonio Cubillo, Estela Vega, et al.
British Journal of Cancer|December 12, 2018
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Therapeutic Advances in Medical Oncology|January 9, 2025
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in SpainRafael Álvarez-Gallego, Roberto Pazo-Cid, Borja López de San Vicente, et al.
British Journal of Cancer|March 29, 2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysisUwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, et al.
Pageof 6